Results 41 to 50 of about 4,782 (272)

Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety

open access: yesInternational Journal of COPD, 2022
Samy Suissa,1,2 Sophie Dell’Aniello,1 Pierre Ernst1,2 1Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital, Montreal, Quebec, Canada; 2Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec ...
Suissa S, Dell'Aniello S, Ernst P
doaj  

Inhalation therapy in the next decade : Determinants of adherence to treatment in asthma and COPD [PDF]

open access: yes, 2018
Peer reviewedPublisher ...
Amaducci, Sandro   +36 more
core   +5 more sources

The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD : current evidence and future prospects [PDF]

open access: yes, 2019
Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto (R) or Stiolto (R) is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting ...
Brusselle, Guy, Derom, Eric, Joos, Guy
core   +1 more source

New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma [PDF]

open access: yes, 2017
Introduction: Inhaled corticosteroids (ICS) alone or in combination with an inhaled long-acting beta2-agonist (LABA) are the preferred long-term treatment for adults and adolescents with symptomatic asthma.
Thomson, Neil C.
core   +1 more source

Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life. [PDF]

open access: yes, 2018
INTRODUCTION: Directly recorded patient experience of symptoms and health-related quality of life (HRQoL) can complement lung function and exacerbation rate data in chronic obstructive pulmonary disease (COPD) clinical studies.
Birk, R   +7 more
core   +2 more sources

Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. [PDF]

open access: yes, 2014
BACKGROUND: Inhaled corticosteroids (ICS) are anti-inflammatory drugs that have proven benefits for people with worsening symptoms of chronic obstructive pulmonary disease (COPD) and repeated exacerbations.
Agarwal   +163 more
core   +1 more source

The IMPACT of tripleversusdual single-inhaler therapy on exacerbations of COPD [PDF]

open access: yesBreathe, 2018
In the IMPACT trial, triple inhalation therapy resulted in a lower rate of moderate or severe COPD exacerbations compared with either dual therapy with ICS/LABA or LAMA/LABA, but pneumonia rates were increased. http://ow.ly/pYJn30mgpFp.
openaire   +2 more sources

Benefit:Risk Profile of Budesonide in Obstructive Airways Disease [PDF]

open access: yes, 2019
Airway inflammation is a major contributing factor in both asthma and chronic obstructive pulmonary disease (COPD) and represents an important target for treatment.
Brattsand, Ralph   +2 more
core   +3 more sources

Combination inhaled steroid and long-acting beta-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease (Review) [PDF]

open access: yes, 2011
Background The long-acting bronchodilator tiotropium and single inhaler combination therapy of inhaled corticosteroids and long-acting beta(2)-agonists are both commonly used for maintenance treatment of chronic obstructive pulmonary disease.
Appleton   +10 more
core   +1 more source

Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease [PDF]

open access: yes, 2016
Acknowledgments The data in this article have been partly presented in preliminary abstract form as a poster at the winter meeting of the British Thoracic Society, London, 2 December 2015 (10.1136/thoraxjnl-2015-207770.161).Peer reviewedPublisher ...
Anderson   +28 more
core   +3 more sources

Home - About - Disclaimer - Privacy